DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management

Ma, Xianxiong; Cheng, Jiancheng; Zhao, Peng; Li, Lei; Tao, Kaixiong; Chen, Hengyu

doi:10.1111/jcmm.15393

Cited by 20 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We applied Cox regression analyses to assess the independent prognostic values of the signature and other clinical characteristics. To estimate the likelihood of survival, a nomogram was constructed based on the risk score and clinical features by using the R package of “rms” ( 41 ), which were analyzed using multivariate Cox regression analysis. And the prognostic ability of the nomogram was weighed by C-index, ROC, and calibration plots ( 41 ).…”

Section: Methodsmentioning

confidence: 99%

Identification of a Novel Glycolysis-Related Gene Signature for Predicting Breast Cancer Survival

et al. 2021

View full text Add to dashboard Cite

To identify a glycolysis-related gene signature for the evaluation of prognosis in patients with breast cancer, we analyzed the data of a training set from TCGA database and four validation cohorts from the GEO and ICGC databases which included 1,632 patients with breast cancer. We conducted GSEA, univariate Cox regression, LASSO, and multiple Cox regression analysis. Finally, an 11-gene signature related to glycolysis for predicting survival in patients with breast cancer was developed. And Kaplan–Meier analysis and ROC analyses suggested that the signature showed a good prognostic ability for BC in the TCGA, ICGC, and GEO datasets. The analyses of univariate Cox regression and multivariate Cox regression revealed that it’s an important prognostic factor independent of multiple clinical features. Moreover, a prognostic nomogram, combining the gene signature and clinical characteristics of patients, was constructed. These findings provide insights into the identification of breast cancer patients with a poor prognosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Identification of a Novel Glycolysis-Related Gene Signature for Predicting Breast Cancer Survival

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, more emphasis should be placed on genomics, epigenomics, and the analysis of patient tumor samples before treatment regimens. A few DNA methylation-related prognostic signatures have been reported in cancer, including melanoma [13], breast cancer [14], and lung adenocarcinoma [15]. These studies suggest that DNA methylation-related prognostic signatures can provide promising cancer biomarkers.…”

Section: Discussionmentioning

confidence: 83%

Development and validation of a DNA methylation signature to predict the progression-free survival in patients with advanced-stage ovarian cancer

Fan

Gao

Qin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ovarian cancer (OC) is a disease characterized by late-stage presentation and poor prognosis. Our aim was to identify a DNA methylation signature for predicting progression-free survival (PFS) of patients with advanced-stage OC.Methods: A bioinformatics analysis was performed to identify methylation sites that are relevant to PFS and develop a DNA methylation signature. A total of 501 patients with advanced-stage OC who were identified from the Cancer Genome Atlas (TCGA) were enrolled as a training cohort, and 108 patients with advanced-stage OC from GSE65820 were used as a validation cohort.Results: A DNA methylation signature was constructed on the basis of five methylation sites. We found that patients with OC in the training and validation cohorts could be stratified, based on the DNA methylation signature, into high- and low-risk groups with distinct prognosis. Different cancer-related pathways were enriched between these two groups. Finally, a nomogram that integrated the methylation signature risk score and clinical stage was established, and the nomogram performed well.Conclusions: The DNA methylation signature provides a promising prognostic biomarker for patients with advanced-stage OC and may help to optimize clinical management.

show abstract

“…LUAD is one of the most common malignancies worldwide [4,[20][21][22]. Due to the lack of effective diagnosis and treatment, its treatment effect is still unsatisfactory [23][24][25]. circRNA is a novel non-coding RNA.…”

Section: Discussionmentioning

confidence: 99%

circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis

Wang

2021

Cancer Cell Int

View full text Add to dashboard Cite

Background Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer, with a poor prognosis. The roles of circular RNAs (circRNAs) in tumors have been initially clarified. In this study, we probed into the functions and underlying molecular mechanisms of circ-ANXA7 in LUAD. Methods According to circRNA microarray analysis based on 40 pairs of LUAD tissues and non-tumor tissues, a novel circ-ANXA7 was up-regulated in LUAD, which was verified in LUAD tissues and cells by RT-qPCR. Correlation between its expression and clinical features of LUAD was analyzed. When transfected with sh-circ-ANXA7, proliferation, invasion, and migration of LUAD cells were determined by a series of functional assays. Furthermore, tumor growth was investigated in nude mice injected with sh-circ-ANXA7. Dual luciferase report and gain and loss assays were used to confirm the relationships between circ-ANXA7 and miR-331, miR-331 and LAD1. Results circ-ANXA7 was up-regulated in LUAD tissues and cells. Its high expression promoted proliferation, migration, and invasion of LUAD cells as well as tumor growth. High circ-ANXA7 expression usually predicted a poorer prognosis for LUAD patients. Furthermore, circ-ANXA7 could accelerate proliferation and invasion of LUAD cells by targeting miR-331. miR-331 directly bound to the 3′-UTR of LAD1. LAD1 induced proliferation and invasion of LUAD cells, which was reversed after co-transfection with circ-ANXA7 knockdown. LAD1 expression could be an independent prognostic marker for LUAD by univariate and multivariate analysis. Conclusions Our research identified a novel circ-ANXA7 for LUAD, which could facilitate proliferation, migration, and invasion of LUAD cells by miR-331/ LAD1 axis. circ-ANXA7 could become a promising prognosis and treatment target for LUAD.

show abstract

DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management

Cited by 20 publications

References 37 publications

Identification of a Novel Glycolysis-Related Gene Signature for Predicting Breast Cancer Survival

Identification of a Novel Glycolysis-Related Gene Signature for Predicting Breast Cancer Survival

Development and validation of a DNA methylation signature to predict the progression-free survival in patients with advanced-stage ovarian cancer

circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis

Contact Info

Product

Resources

About